VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

GU Cancers 2021 | Key updates in bladder cancer from ASCO GU 2021

Guru Sonpavde, MD, Dana-Farber Cancer Institute, Boston, MA, shares his highlights from ASCO GU 2021, in particular discussing the Phase III CheckMate 274 trial (NCT02632409) investigating nivolumab versus placebo in patients with high-risk muscle invasive urothelial carcinoma (MIUC) who have undergone radical surgery. The trial found that nivolumab improved disease-free survival (DFS) versus placebo in both randomized patients and patients with PD-L1 expression over 1%. Dr Sonpavde also outlines the Phase III AMBASSADOR trial (NCT03244384) evaluating pembrolizumab after surgery for MIUC, a retrospective analysis of the results of the Phase III IMvigor010 trial (NCT02450331) investigating atezolizumab in MIUC, and the Phase II RETAIN BLADDER trial (NCT02710734) of risk-enabled therapy after initiating neoadjuvant chemotherapy for bladder cancer. Finally, Dr Sonpavde discusses the results of the Phase II/III QUILT-3.032 trial (NCT03022825) of a IL-15 superagonist, N-803, with BCG for the treatment of non muscle invasive bladder cancer that is unresponsive to BCG. This interview took place during the 2021 Genitourinary Cancers Symposium.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter